… tolerated and without adverse pharmacodynamic interaction; combination treatment did not
affect the low‐density lipoprotein cholesterol‐lowering efficacy and safety of atorvastatin, or …

… /pharmacodynamic model, based on preliminary efficacy from the Phase II study, as well as
on pharmacodynamic … individuals and animal pharmacological studies suggested that the …

… objectives of this study were to assess the safety profile and pharmacokinetics of increasing
doses of INO-1001. Secondary objectives were to assess its pharmacodynamic profile using …

… This study examined the safety, pharmacodynamics, and pharmacokinetics of multiple doses
of … and pharmacodynamics, before the inception of trials to assess its therapeutic efficacy. …

… -ranging phase II study were based on the results of the phase I study in patients with locally
recurrent or metastatic breast cancer. The phase I study evaluated doses ranging from 200 …

… The present study provides new data on the safety, pharmacodynamic effects, and
clinical efficacy of xemilofiban. The optimal level of platelet inhibition required to achieve …

… This study evaluated the safety and pharmacodynamics of single, intravenous doses (0.025,
0.05, and 0.1 mg/kg) of Hematide in 28 healthy male volunteers. All doses of Hematide …

… glycemic control in youth with T2D. Further controlled trials evaluating the efficacy and safety
of incretin agents in pediatric T2D are currently in progress evaluating exenatide, sitagliptin, …

… strategies that optimize efficacy while maintaining the compound’s safety. In this article, we
review the clinical pharmacokinetics, pharmacodynamics, safety, and efficacy of LAmB in a …

… The pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of denosumab
… evaluated for the first time in this Phase I study in healthy Chinese adults. Data from this study …